Skip to main content

Select Drug Profiles

Practice Management

Lessons from the Leucovorin Shortages Between 2009 and 2012 in a Medicare Advantage Population: Where Do We Go from Here?

Mary S. Hayes, PharmD, S. Lane Slabaugh, PharmD, MBA, Melea A. Ward, PharmD, MS, Yihua Xu, PhD

Stakeholder Perspective

Drug Shortages Are Costly to Patients and to Payers

by Joseph P. Fuhr, Jr, PhD

Practice Management

Offering Lung Cancer Screening to High-Risk Medicare Beneficiaries Saves Lives and Is Cost-Effective: An Actuarial Analysis

Ellynne Dec, ASA, MAAA, Claudia I. Henschke, PhD, MD, David F. Yankelevitz, MD, Rowena Yip, MPH, Bruce S. Pyenson, FSA, MAAA

Stakeholder Perspective

Cost-Effectiveness and the Medicare Budget

by Joseph R. Antos, PhD

Original Research

Impact of Linaclotide Treatment on Work Productivity and Activity Impairment in Adults with Irritable Bowel Syndrome with Constipation: Results from 2 Randomized, Double-Blind, Placebo-Controlled Phase 3 Trials

Jessica L. Buono, MPH, Robyn T. Carson, MPH, Jeffrey M. Johnston, MD, Phil Sarocco, RPh, MSc, Stavros Tourkodimitris, PhD

Stakeholder Perspective

Patient-Reported Outcomes Matter

by Walid F. Gellad, MD, MPH

Beyond Paternalism

David B. Nash, MD, MBA

Population Health and the Assessment of Value

Joseph D. Jackson, PhD

Stakeholder Integration Needed to Address a Flawed Reimbursement System

Matthew Mitchell, PharmD, MBA, FAMCP

Breast Cancer, Oncology

ALTTO: Dual Anti-HER2 Adjuvant Therapy No Better than Trastuzumab Alone

Breast Cancer, Oncology

Less May Be “More” with Zoledronic Acid

Caroline Helwick

Breast Cancer, Oncology

Adjuvant Exemestane More Effective than Tamoxifen in Early-Stage Breast Cancer

Multiple Myeloma, Oncology

Novel Drug Classes Make News in Multiple Myeloma

Caroline Helwick

Page 145 of 244
Results 1441 - 1450 of 2434